Healthcare Services

Adult Malignant Glioma Therapeutics Market Industry Forecast Reflecting Growth To $3.94 Billion By 2030

May 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Growth In Market Value Is Anticipated For The Adult Malignant Glioma Therapeutics Market Between 2026 And 2030?

The adult malignant glioma therapeutics market size has experienced strong growth over the last few years. This market is anticipated to expand from $2.47 billion in 2025 to $2.7 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.1%. The historical expansion of the market is largely due to factors including the restricted therapeutic options for malignant gliomas, a continued reliance on standard chemotherapy and radiotherapy, the growing prevalence of adult brain tumors, the development of hospital oncology services, and an increased awareness regarding glioma treatment needs.

The adult malignant glioma therapeutics market size is projected to experience robust expansion in the coming years. This market is forecast to reach $3.94 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.9%. Key drivers for this growth during the projection period include the advancement of targeted molecular therapies, the broadening of clinical trials for innovative glioma treatments, increased funding in precision oncology, a surge in partnerships between biotechnology firms and healthcare entities, and the uptake of sophisticated radiotherapy and combination therapeutic methods. Prominent trends anticipated in the forecast timeframe encompass the escalating creation of targeted glioma interventions, a growing acceptance of integrated treatment strategies, the proliferation of experimental and tailored therapies, an intensified commitment to enhancing patients’ quality of life, and the greater deployment of advanced radiotherapy technologies.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13178&type=smp

What Core Drivers Are Transforming The Adult Malignant Glioma Therapeutics Market?

Financial backing from governments for brain cancer studies is projected to boost the expansion of the adult malignant glioma therapeutics market in the future. This type of funding denotes monetary aid extended by governmental bodies, be it federal, state, or local, to diverse entities like organizations, initiatives, projects, programs, or individuals. Such government investment in brain cancer research can benefit adult malignant glioma therapeutics through aiding in the creation of new treatments, personalized drug development, targeting pyrimidine synthesis, and facilitating orphan drug approval. As an illustration, during June 2023, the Australian Department of Health and Aged Care, an Australian governmental agency, launched the Australian Brain Cancer Mission, allocating $136.66 million towards brain cancer research. This particular initiative seeks to double the survival rates and consequently enhance the life quality for individuals suffering from brain cancer, encompassing anaplastic astrocytoma. Consequently, government financial support for brain cancer investigations propels the adult malignant glioma therapeutics market.

Which Segment Divisions Form The Structure Of The Adult Malignant Glioma Therapeutics Market?

The adult malignant glioma therapeutics market covered in this report is segmented –

1) By Type Of Disease: Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Other Types

2) By Therapy: Chemotherapy, Targeted Therapy, Radiotherapy, Other Therapies

3) By End-User: Hospitals, Specialty Clinics, Cancer And Radiation Therapy Centers, Other End Users

Subsegments:

1) By Glioblastoma Multiforme: Standard Treatments, Experimental Therapies

2) By Anaplastic Astrocytoma: Chemotherapy Options, Targeted Therapies

3) By Anaplastic Oligodendroglioma: Radiation Therapy, Combination Therapies

4) By Anaplastic Oligoastrocytoma: Surgical Interventions, Adjuvant Therapies

5) By Other Types: Rare Gliomas, Emerging Therapies

What Trends Are Influencing The Adult Malignant Glioma Therapeutics Market?

Leading companies in the adult malignant glioma therapeutics market are developing innovative products, such as small molecule targeted degraders, to offer improved customer service. A small-molecule targeted degrader is a drug that employs small molecules to induce the breakdown of specific proteins by targeting both the protein of interest (POI) and an E3 ubiquitin ligase. For instance, in February 2023, Beactica Therapeutics AB, a precision oncology company based in Sweden, obtained orphan drug designation approval from the U.S. Food and Drug Administration (FDA) for BEA-17, designed to treat glioblastoma (GBM). This compound is a small-molecule targeted degrader of the epigenetic enzyme LSD1 and its co-factor CoREST, both implicated in the development of various cancers, including GBM. BEA-17 achieves its effect by degrading LSD1 and CoREST, which results in the reactivation of tumor suppressor genes and the inhibition of cancer cell proliferation.

Which Organizations Are Operating Within The Adult Malignant Glioma Therapeutics Market?

Major companies operating in the adult malignant glioma therapeutics market are Johnson & Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche Ltd., Allergan plc, AbbVie Inc., Novartis AG, Bayer AG, Merck & Co Inc., GlaxoSmithKline plc, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., GT Medical Technologies Inc., Lupin Limited, Mylan NV, Sanofi SA, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Limited, Genentech Inc., Amneal Pharmaceuticals LLC, Emcure Pharmaceuticals Limited, Novocure Ltd., Arbour Pharmaceuticals LLC, Basilea Pharmaceuticals Ltd.

Access The Complete Adult Malignant Glioma Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/adult-malignant-glioma-therapeutics-global-market-report

Which Region Is The Primary Market For The Adult Malignant Glioma Therapeutics Market?

North America was the largest region in the adult malignant glioma therapeutics market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the adult malignant glioma therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Adult Malignant Glioma Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=13178&type=smp

Browse Through More Reports Similar to the Global Adult Malignant Glioma Therapeutics Market 2026, By The Business Research Company

Glioma Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/glioma-treatment-global-market-report

Pontine Glioma Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/pontine-glioma-drugs-global-market-report

Brain Tumor Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/brain-tumor-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795